Liability Data News Today

~ PEDMARK® Net Product Revenue of $6.5 Million, a 96% Increase Compared to Second Quarter ~ ~ Strong Commercial Uptake Underscoring Significant Unmet Medical Need ~ ~ Received Approval in October...

~ Strong PEDMARK® Commercial Momentum Building in 2023 with Broad Payor and Medicaid Coverage ~ ~ PEDMARK® Permanent J-Code Effective April 1, 2023 ~ ~ Recent Positive CHMP Opinion in EU... | May 11, 2023

~ U.S. Commercial Team in Place with PEDMARK® Launch Off to Solid Start Following FDA Approval of PEDMARK® in September 2022 ~ ~ Company Has Approximately $23.8 Million in Cash ~ ... | March 30, 2023

Caution Concerning Forward-Looking Statements The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated... | March 29, 2023

(2022-11-11 | TSX:FRX) Fennec Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Business Update

~ PEDMARKTM FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for September 23, 2022 ~ ~ Commercial Team Built Out In Anticipation of U.S....

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

~ Resubmission of NDA for PEDMARK™ Targeted for the First Quarter of 2022 ~ ~ Company has Approximately $21.1 Million in Cash and $5 Million of Funded...